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Background: Bisphosphonates, including zoledronate, target osteoclasts and are widely used in 
the treatment of osteoporosis and other bone resorption diseases, despite side effects that include 
damaging the stomach epithelium. Beneficial and adverse effects on other organ systems, including 
the cardiovascular system, have also been described and could impact on the use of bisphospho-
nates as therapeutic agents. Vascular smooth muscle cells (VSMCs) are major constituents of 
the normal vascular wall and have a key role in intimal thickening and atherosclerosis, in part by 
secreting MMPs that remodel the extracellular matrix and cleave cell surface proteins or secreted 
mediators. In this study, we investigated the effects of zoledronate on MMP expression.
Methods: Rat VSMCs were stimulated by PDGF (50 ng/mL) plus TNF-α (10 ng/mL) or left 
unstimulated for a further 24 hours in serum-free medium. In other series of experiments, cells 
were pre-treated either with SC-514 (50 μM) or with apocynin (20 nM) for 2 hours, then zole-
dronate (100 μM) was added into 2% fetal calf serum containing medium for 24 hours.
Results and discussion: Using isolated rat VSMCs in culture, zoledronate (100 μM) increased 
MMP-9 and -13 mRNA expressions but inhibited MMP-2 expression. MMP-9 and MMP-13 
up-regulation was shown to depend on the NF-κB pathway; and this was activated by zole-
dronate. Furthermore, zoledronate elevated the levels of reactive oxygen species detected by 
either dichlorofluorescein in isolated VSMCs or lucigenin enhanced chemiluminescence in rat 
aortic rings in vitro. Apocynin, an inhibitor of NADPH oxidase, reversed NF-κB activation and 
MMP-9 and MMP-13 up-regulation by zoledronate.
Conclusion: We conclude that zoledronate increases MMP-9 and MMP-13 expressions in rat 
VSMCs dependent upon stimulation of the NF-κB pathway by reactive oxygen species. Effects 
on MMP expression may contribute to the pharmacologic profile of bisphosphonates.
Keywords: vascular smooth muscle cell, matrix metalloproteinase, bisphosphonate, reactive 
oxygen species, zoledronate
Introduction
Bisphosphonates are widely used clinically for the treatment of osteoporosis and bone 
metastasis. Although they primarily target osteoclasts, adverse and beneficial effects 
on other organ systems have been described. Destruction of the gastric epithelium 
by high concentrations of bisphosphonates is a recognized off-target effect. On the 
contrary, beneficial effects on atherosclerosis have also been described,1–3 although 
the precise mechanisms involved have not been elucidated.
Migration and proliferation of vascular smooth muscle cells (VSMCs) play key 
roles in the development of vascular proliferative diseases such as atherosclerosis and 
restenosis.4 Moreover, previous studies showed that bisphosphonates inhibit adhesion of 
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VSMCs to extracellular matrix components in tissue culture, 
as well as their proliferation and migration.5,6 The end result is 
decreased neointimal hyperplasia both in preclinical and clini-
cal investigations.7–9 MMPs play a variety of roles in normal 
vascular physiology and pathology. For example, increased 
expression of MMP-13 (especially in rodents) can degrade 
fibrillar type I and III collagen, thereby increasing atheroscle-
rotic plaque’s vulnerability to rupture.10 Conversely, MMP-2 
and MMP-9 stimulate migration and proliferation of VSMCs 
by degrading basement components including type IV collagen. 
This contributes to restenosis but may prevent plaque rupture 
thanks to formation of a more stable plaque cap.11
Bisphosphonates have been reported to inhibit expres-
sion and activity of some MMPs in different steps of cancer 
progression.12–14 However, the effects of bisphosphonates 
on MMPs implicated in the pathogenesis of atherosclerosis 
and restenosis have not been elucidated. In this study, we 
therefore investigated the effects of zoledronate, which is 
a highly potent bisphosphonate, on MMP-2, MMP-9, and 
MMP-13 expressions in rat VSMCs.
Materials and methods
cell culture
Primary rat cells
Male Sprague Dawley rats were killed by cervical dislocation 
in accordance with the Directive 2010/63/EU of the European 
Parliament. Approval was granted by the University of Bristol 
ethical review board. VSMCs (four separate preparations from 
different rats) were obtained by the explant method from tho-
racic aortas and were cultured in Dulbecco’s Modified Eagle’s 
Medium (Lonza, Basel, Switzerland) containing 10% fetal calf 
serum (FCS), penicillin (100 mg/mL), streptomycin (100 U/
mL), and L-glutamine (2 mM). VSMCs were used between 
passage 6 and 8 in the experiments, which is within the limits 
(passage 3–8) of previous studies.15 Reduced serum (2%) or 
serum-free conditions were used in some incubations to avoid 
interfering with the zymographic assays, and were well toler-
ated by VSMCs.16
Treatment of the cells
Zoledronate (Novartis International AG, Basel, Switzerland) 
was obtained as a 2.94 mM sterile, neutral aqueous solution 
for intravenous infusion containing 4 mg of zoledronate, 
220 mg mannitol, and 24 mg sodium citrate in 5 mL. Cells 
were seeded into 12-well plates. When they became conflu-
ent, they were pre-treated with zoledronate to a final concen-
tration of 100 μM zoledronate or kept as untreated in 2% FCS 
containing medium for 24 hours. Given the high dilution and 
innocuous nature of the vehicle, untreated cells were used 
as a control. Cells were stimulated by PDGF (50 ng/mL) 
plus TNF-α (10 ng/mL) or left unstimulated for a further 
24 hours in serum-free medium. In other series of experi-
ments, cells were pre-treated either with SC-514 (Cayman 
Chemicals MA, USA), (50 μM)17 or with apocynin (20 nM) 
for 2 hours, then zoledronate (100 μM) was added into 2% 
FCS containing medium for 24 hours.
real-time polymerase chain reaction 
(Pcr) analysis
Total RNA were extracted from VSMCs using the total RNA 
extraction kit (Ambion, Thermo Fisher Scientific, Waltham, 
MA, USA), according to the manufacturer’s instructions. 
Extracted RNA was quantified using Nanodrop™ 1000 
Spectrophotometer (Thermo Fisher Scientific) and reverse 
transcribed using a Roche Reverse Transcription Kit 
(Hoffman-La Roche Ltd., Basel, Switzerland) (100 ng RNA 
per reaction). A genomic DNA removal step was included, 
and the resulting cDNA was diluted in 10 mM Tris-HCl, 
pH 8. Real-time quantitative PCR was performed in Illumina 
Eco Real-Time PCR with Roche SYBR Green Master Mix 
and primers for MMP-2, MMP-9, MMP-13, IκB, and 36B4, 
which is a housekeeping gene. Primers are listed in Table 1. 
Table 1 Primer sequences used for real-time polymerase chain reaction
Gene symbol Accession number Primer sequences
MMP-2 nM_031054 F: gggagcgcaaggaTggaggcacga
r: ccagcaggcagcacaggacgcaga
MMP-9 nM_031055 F: aggcgccgTggTccccacTTacTT
r: gcagggTTTgccgTcTccgTTgcc
MMP-13 nM_133530 F: TcgcaTTgTgagagTcaTgccaaca
r: TgTggTTccagccacgcaTagTca
IκB nM_001105720 F: cTacTggacgaccgccacgacagc
r: cgaggcggaTcTccTgcagcTccTTg
36B4 nM_022402 F: gccagcgaagccacgcTgcTgaac
Note: national center for Biotechnology information accession number, gene symbol, and sequences of forward (F) and reverse (r) primers.
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To confirm amplification specificity, PCR products from 
each primer pair were subjected to agarose gel electro-
phoresis. Relative mRNA expression levels were calcu-
lated by using the Delta-Delta Ct method using 36B4 as a 
normalization control.
Western blotting and gelatin zymography
Conditioned media of the cells were collected and con-
centrated using centrifugal filter units (Merck Millipore, 
Billerica, MA, USA). Cells were lysed in sodium dodecyl 
sulfate (SDS) buffer (2% SDS [w/v], 16% glycerol [v/v], 
and 50 mM Tris [pH 6.8]). Protein concentration in lysates 
was measured using BCA Protein Assay Kit (Thermo Fisher 
Scientific) and was used to normalize loading of gels.
MMP-9 activity in conditioned medium was determined 
by gelatin zymography as described previously.17 Briefly, 
7.5% polyacrylamide gels containing 2 mg/mL of gelatin were 
subjected to electrophoresis. Following electrophoresis, SDS 
was removed by washing in 2.5% Triton X-100. Gels then 
were incubated at 37°C for 48 hours in incubation buffer (50 
mM Tris-HCl, pH 8.0, 50 mM NaCl, 10 mM CaCl
2
, and 0.05% 
Triton X-100). Ethylenediaminetetraacetic acid (EDTA) 
inhibits MMP activity by chelating Zn2+ on enzymes’ catalytic 
domain. In order to verify if the detected bands were MMP-2 
and -9, another gel was incubated in calcium-free incubation 
solution containing 10 mM EDTA. After the incubation 
period, gels were stained in 0.2% Coomassie Brilliant Blue. 
Images of the gels were captured with a scanner. Gelatinase 
activity was detected as clear bands on dark backgrounds.
For Western blotting, equal total protein concentrations 
(see above) were loaded on 8%–10% polyacrylamide gels 
and transferred onto polyvinylidene difluoride membranes as 
described previously.18 These were blocked for an hour in 5% 
(w/v) skimmed milk powder and incubated overnight at 4°C 
with anti-MMP-13 (catalog no ab39012; Abcam, Cambridge, 
UK) (1:2,000 in 5% BSA:Tris-buffered saline). Bound pri-
mary antibodies were detected by horseradish peroxidase-
conjugated antibodies (Sigma-Aldrich Co., St Louis, MO, 
USA; catalog no A6154) (1:5,000 in 5% BSA:Tris-buffered 
saline) and enhanced chemiluminescence (Amersham Inter-
national, Buckinghamshire, UK).
Detection of reactive oxygen species 
(rOs) in rat thoracic aortic rings
This study was approved by the Local Ethics Committee of 
Dokuz Eylul University School of Medicine. All animals received 
care in compliance with the principles of laboratory animal care 
formulated by the National Society for Medical Research and 
with the Guide for the Care and Use of Laboratory Animals 
prepared by the Institute of Laboratory Animal Resources.
Levels of superoxide anion and other ROS in aortic rings 
were measured as previously described.19 In this study, Wistar 
rats were euthanized by decapitation under ketamine/xylazine 
anesthesia. The thoracic aorta segment was dissected. Fol-
lowing careful removal of loose connective tissue, thoracic 
aorta was cut into 2 mm rings. The rings were then transferred 
into Dulbecco’s Modified Eagle’s Medium/F12 (Gibco, 
Thermo Fisher Scientific) cell culture medium containing 2% 
FCS immediately. The rings were incubated in cell culture 
medium in the presence or absence of 100 μM zoledronate 
for 24 hours in a humidified atmosphere containing 5% 
CO
2
 at 37°C. Subsequently, aortic rings were transferred 
to solid white well plates containing 200 mL of HEPES-
buffered Krebs-Henseleit solution (pH 7.4). After addition 
of chemiluminescence enhancers, lucigenin or luminol (final 
concentration of 5 μmol/L for either), ROS were quantified 
using a multi-plate reader (Victor III-1420; PerkinElmer 
Inc., Waltham, MA, USA). Counts were obtained every 10 
seconds and normalized per mg of wet tissue weight. Results 
were expressed as the area under curve for a counting period 
of 5 minutes of relative light units (rlu)/wet tissue (mg).
statistical analysis
Statistical analyses were performed using the Prism software 
v.4 (GraphPad Software, Inc., La Jolla, CA, USA). Multiple 
comparisons were subjected to one-way analysis of variance 
followed by post hoc Bonferroni correction. Paired Student’s 
t-tests were performed to compare means of lucigenin/
luminol measurements. When necessary, data were normal-
ized by log transformation. Normalized data were expressed 
as mean ± standard error of the mean P#0.05 was considered 
statistically significant.
Results
effects of zoledronate on expression of 
MMPs with and without induction by 
PDgF and TnF-α
Because of their diverse roles and regulation patterns, we stud-
ied constitutively expressed gelatinase, MMP-2, together with 
another gelatinase, MMP-9, and a collagenase, MMP-13, that 
could be induced by a combination of PDGF and TNF-α.
gelatinase a/MMP-2
MMP-2 was constitutively expressed in VSMCs (Figure 1A, B), 
in agreement with previous studies.16 Zoledronate pre-treat-
ment did not change constitutive MMP-2 mRNA levels 
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(Figure 1A). PDGF plus TNF-α treatment significantly 
decreased MMP-2 mRNA levels to a similar extent in 
untreated and zoledronate pre-treated cells (Figure 1A). This 
was confirmed by zymography in which MMP-2 appeared 
as a major 72 kDa band (Figure 1B) that disappeared on 
incubation in the presence of EDTA (lower panel).
gelatinase B/MMP-9
MMP-9 was expressed at barely detectable levels in quies-
cent VSMCs (Figure 1B, C) also in agreement with previous 
work.16 However, zoledronate pre-treatment significantly 
increased MMP-9 mRNA levels (Figure 1C). PDGF plus 
TNF-α induced even higher MMP-9 mRNA levels and this 
effect was enhanced by zoledronate pre-treatment (Figure 1C). 
Consistent with this, only after PDGF plus TNF-α induction 
of zoledronate pre-treated cells was MMP-9 protein detectable 
by zymography as a 92 kDa band (Figure 1B) that disappeared 
on incubation in the presence of EDTA (lower panel).
collagenase 3/ MMP-13
The effects of zoledronate on MMP-13 expression were similar 
to those on MMP-9. Zoledronate pre-treatment significantly 
increased MMP-13 mRNA and protein levels in control cells 
(Figure 1D, E). PDGF plus TNF-α induction increased MMP-13 
mRNA and protein levels even further, and these were additively 
increased in zoledronate treated cells (Figure 1D, E).
role of nF-κB in MMP-9 and MMP-13 
induction
The NF-κB pathway was previously shown to play an 
essential role in up-regulation of MMP-1, MMP-3, and 
MMP-9 in rabbit and human VSMCs using gene transfer 
of a dominant negative form of the inhibitor of κB, IκBα.16 
We also showed17 that induction of several MMPs in human 
monocytes can be reversed by using SC-514, which is a selec-
tive inhibitor of IκB kinase 2.20 We therefore used SC-514 
to investigate whether NF-κB also mediates MMP-9 and 
MMP-13 up-regulation in rat VSMCs. SC-514 had no effect 
on the barely detectable levels of MMP-9 (Figure 2A) or 
MMP-13 (Figure 2B) mRNA in dimethyl sulfoxide treated 
cells. However, SC-514 strongly inhibited induction of 
MMP-9 and MMP-13 by PDGF plus TNF-α, thereby dem-
onstrating the importance of NF-κB in up-regulation of both 
these MMPs. To investigate whether zoledronate activated 
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Figure 1 effects of PDgF plus TnF-α and zoledronate (48 hours) on MMP-2, -9, and -13.
Notes: (A) MMP-2 mrna expression. ***P#0.001, *P#0.05 vs control-Untreated, n=3. (B) MMP-2 and MMP-9 protein expressions. a representative zymogram a: no 
induction; b: PDgF (50 ng/ml) + TnF-α-induced (10 ng/ml); c: PDgF (50 ng/ml) + TnF-α-induced (50 ng/ml). (C) MMP-9 mrna expression. **P#0.01, ***P#0.001 vs 
control-untreated, ##P#0.01 vs control-zoledronate (n=3). (D) MMP-13 mrna expression **P#0.01, ***P#0.001 vs control untreated, ##P#0.01 vs control-zoledronate 
(n=3). (E) Protein expression of MMP-13 by Western blotting. lanes no induction (c); Zoledronate (100 μM) (z); PDgF (50 ng/ml) + TnF-α-induced (50 ng/ml) (p+t); 
PDgF + TnF-α + Zoledronate (p+t+z).
Abbreviation: eDTa, ethylenediaminetetraacetic acid.
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the NF-κB pathway in VSMCs, we measured expression 
of IκBα mRNA because its promoter is a direct target of 
NF-κB activation in a process designed to cause feedback 
inhibition.21 Detectable levels of IκBα mRNA were present 
in quiescent VSMCs (Figure 2C) but, similarly to MMP-9 
and MMP-13, these were significantly augmented by pre-
treatment with zoledronate (Figure 2C). PDGF plus TNF-α 
increased IκBα mRNA levels even further and this was also 
enhanced by zoledronate pre-treatment (Figure 2C).
rOs production in zoledronate treated 
isolated VsMcs and aortas
The NF-κB pathway is known to be sensitive to ROS pro-
duction in VSMCs, independently of the effects of inflam-
matory mediators.22 We therefore investigated whether ROS 
production in response to zoledronate might be responsible 
for activation of the NF-κB pathway, and hence MMP-9 and 
MMP-13 induction. Firstly, to confirm the activation of ROS, 
a dichlorofluorescein assay was performed to quantify cel-
lular oxidative stress in isolated rat VSMCs. The cells were 
treated with zoledronate or PDGF plus TNF-α, with untreated 
cells as control. The results showed clearly that zoledronate 
treatment increased ROS levels, whereas no significant 
effect was observed with PDGF plus TNF-α (Figure 3A). 
For further confirmation, ROS levels were measured by using 
lucigenin or luminol in intact rat aortic tissue studied ex vivo. 
Incubation of rat aortic rings with zoledronate (100 μM) for 
24 hours significantly elevated lucigenin enhanced chemilu-
minescence by approximately 2.5 times compared to control, 
untreated aortic rings (Figure 3B). The data for luminol 
enhanced chemiluminescence showed the same trend but 
was not significant (P=0.116, Figure 3B).
effects of naDPh oxidase inhibitor, 
apocynin, on induction of MMP-9, MMP-13, 
and iκB mrnas
NADPH oxidase is a prominent source of ROS in VSMCs.23 
We therefore investigated the effects of apocynin, which is an 
inhibitor of NADPH oxidase. Apocynin reversed the eleva-
tion of MMP-9 mRNA levels in zoledronate pre-treated cells 
but had no significant effect on untreated cells (Figure 4A). 
Apocynin significantly decreased MMP-13 mRNA levels in 
untreated cells, and also normalized the high levels of MMP-13 
mRNA expression in zoledronate pre-treated cells (Figure 4B). 
Furthermore, apocynin significantly inhibited NF-κB activa-
tion measured by the increase in mRNA levels of IκB-α in 
zoledronate pre-treated cells, but had no effect on untreated 
cells (Figure 4C).
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Figure 2 evidence for involvement of the nF-κB pathway.
Notes: (A) effects of iκB kinase 2 inhibitor sc-514 (50 μM) were measured on MMP-9 mrna expression. ***P#0.001 untreated vs PDgF plus TnF-α induction, ###P#0.001 
untreated vs sc-514 (n=4). (B) effects of sc-514 (50 μM) were measured on MMP-13 mrna expression. ***P#0.001 untreated vs PDgF plus TnF-α induction, ###P#0.001 
untreated vs sc-514 (n=4). (C) effects of PDgF plus TnF-α induction and zoledronate treatment (48 hours) were measured on iκBα mrna expression levels. ***P#0.01 
vs control – untreated, #P#0.05 untreated vs sc-514 (n=3).
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Discussion
In this study, we investigated the effects of zoledronate in 
primary rat VSMCs on expression of three abundant MMPs 
that are known to influence their migration, proliferation, 
and apoptosis. We chose MMP-2, MMP-9, and MMP-13 
since they show diverse substrate specificity and response 
to induction by PDGF plus TNF-α. Our data, for the first 
time, demonstrated that zoledronate induced expression of 
MMP-9 and MMP-13 but not MMP-2. Then, we investigated 
the possible underlying mechanisms and revealed that zole-
dronate may have a role in ROS production and activation 
of the NF-κB pathway.
As mentioned in the Introduction, bisphosphonates 
have been reported to inhibit expression and activity of 
some MMPs during cancer progression.12–14 However, we 
found that zoledronate increased expressions of MMP-9 and 
MMP-13 in primary rat VSMCs, consonant with other pub-
lished studies. For example, in a published study zoledronate 
administration before tooth extraction was stated to augment 
MMP-9 mRNA levels, protein expression of MMP-9, and 
enzymatic activity of MMP-9 during wound healing. The 
same study also reported that RANKL was at least partially 
responsible for the increased MMP-9 mRNA transcription.24 
Similarly, pamidronate, another nitrogen containing 
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Figure 3 effects of zoledronate on rOs levels in rat VsMcs and aortic rings. 
Notes: (A) ROS levels determined by dichlorofluorescein (DCF) fluorescence were compared in control (c), PDGF (50 ng/mL) plus TNF-α (10 ng/ml) induced (pt) and 
zoledronate pre-treated (zol, 100 μM) cells. *P#0.05 control vs zoledronate (n=4). (B) lucigenin or luminol enhanced chemiluminescence was measured in control and 
100 μM zoledronate pre-treated isolated rat aortic rings. *P#0.05 control vs zoledronate, paired student’s t-test, (n=5).
Abbreviations: rOs, reactive oxygen species; VsMcs, vascular smooth muscle cells; aUc, area under curve; rlU, relative light units.
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Figure 4 effects of apocynin with and without zoledronate on MMP-9, -13, and iκBα.
Notes: (A) MMP-9 mrna expression. **P#0.01, #P#0.05 vs control – zoledronate. (B) MMP-13 mrna expression. *P#0.05, ***P#0.01 vs control – untreated, #P#0.05 
vs control – zoledronate. (C) iκBα mrna expression. *P#0.05 vs control – untreated; #P#0.05 control vs apocynin (n=4).
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bisphosphonate similar to zoledronate, at concentrations of 
30 μM to 300 μM, caused a 5- to 10-fold increase in MMP-9 
mRNA levels in human monocytes.25 Nitrogen containing 
bisphosphonate, alendronate markedly stimulated mRNA 
levels of MMP-13 in primary rat osteoblasts at concentra-
tions higher than 10 μM.26 While these results support our 
basic findings, none of the published studies identified the 
underlying mechanisms.
We showed here that NF-κB activity is essential for 
up-regulation of MMP-9 and MMP-13 in rat VSMCs using 
the competitive inhibitor of κB kinase 2, SC-514.20 SC-514 
can target other unrelated kinases PIM3, PIM1, DYRK1A, 
DYRK3, and Aurora B with similar affinity.27 However, 
MMP-1, MMP-3, and MMP-9 transcription in rabbit and 
human VSMCs16 was also inhibited by adenovirus-mediated 
gene transfer of dominant negative IκBα, which reinforces 
the specific role of NF-κB in MMP-9 induction. Similarly, 
NF-κB activation was shown to be essential for MMP-13 
induction in chondrocytes.28
We hypothesized, furthermore, that zoledronate can 
activate the NF-κB pathway. We found from preliminary 
experiments, that the effects of zoledronate required a 
24-hour pre-incubation (results not shown). This implied that 
any activation of NF-κB would be slow and the method to 
detect it would need to be sensitive to prolonged activation. 
Acute activation is triggered by phosphorylation of IκBα 
which is then targeted for degradation by the 26S proteasome, 
allowing NF-κB dimers to translocate to the nucleus, usually 
within minutes, and activate transcription.21 Subsequently, 
one of the primary targets for active NF-κB is the IκBα gene, 
which drives re-synthesis of the IκBα protein and feeds back 
on the activation cascade.21 As a consequence, IκBα mRNA 
accumulates over an extended time period and we argued that 
this might provide a suitable measurement to investigate the 
effects of zoledronate. In fact, we found clear evidence 
that zoledronate pre-treatment increased IκBα mRNA and 
therefore slowly induced NF-κB activation. However, the 
findings from this study regarding NF-κB require further 
investigation, since the current study did not examine the 
protein expressions of NF-κB.
To answer the question regarding how zoledronate 
activated NF-κB, we set up additional experiment series in 
rat VSMCs. Our results from dichlorofluorescein experi-
ments showed that zoledronate treatment increased ROS 
levels; and this finding was confirmed with an experiment 
on rat thoracic aortic rings by lucigenin measurements. Our 
evidences are consistent with previous experiments dem-
onstrating bisphosphonate induced superoxide production 
in gastric and small intestinal epithelial cells.29 In addition, 
zoledronate administration (100 μg/kg subcutaneously for 
28 days) caused increased oxidative stress and decreased 
antioxidant levels in rabbit livers.30 To confirm the role of 
oxidative stress in NF-κB activation and up-regulation of 
MMP-9 and MMP-13, we showed that apocynin, an inhibitor 
of NADPH oxidase, significantly inhibited these effects of 
zoledronate in VSMCs.
Our results provide new understanding regarding the 
pharmacological effects of bisphosphonates in the cardiovas-
cular system. They are of particular relevance to pathologies, 
such as restenosis and vein graft intimal thickening, where 
there is a predominant role of VSMCs.4 Other sources of 
MMPs, such as macrophages, become relevant in the context 
of atherosclerosis,4 and it would be interesting, in future stud-
ies, to investigate how they respond to zoledronate treatment. 
Moreover, the NF-κB pathway has an established role in the 
induction of several MMPs in diverse cell types including: 
human epithelial cells,31 fibroblasts,32 and macrophages.17 
It is therefore highly likely that the effects of zoledronate that 
we have identified here in rat VSMCs, apply more widely and 
could have a major impact on tissue remodeling and inflam-
matory activation caused by zoledronate. Further studies will 
be needed to address this interesting possibility.
In conclusion, our results conclusively demonstrate that 
zoledronate can increase expression of some MMPs in rat 
VSMCs. Furthermore, this is associated with stimulation of 
ROS production and consequent activation of the NF-κB 
pathway.
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